Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients

Ko, Yoon Ho; Lee, Myung Ah; Hong, Yong-Kil; Lee, Kyung Shik; Park, Hyun Jin; Yoo, Ie Ryung; Kim, Yeon Sil; Kim, Young Kyoon; Jo, Keon Hyun; Wang, Young Pil; Lee, Kyo Young; Kang, Jin Hyoung

doi:10.3904/kjim.2007.22.3.178

Cited by 7 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tawfik et al [26] demonstrated that weekly administration of docetaxel and cisplatin followed by concurrent radiotherapy prolonged PFS to 11.7 months, and OS to 17 months in stage III advanced NSCLC. Whether more frequent drug administration followed by radiotherapy could significantly improve PFS and OS in stage III NSCLC remains unclear [27][28][29] . Drug toxicity is the major barrier for clinical usage.…”

Section: Discussionmentioning

confidence: 99%

A Cost-Effectiveness Analysis of Docetaxel versus Pemetrexed in Second-Line Chemotherapy for Stage IIIb or IV Non-Small Cell Lung Cancer in China

Yang

Chen²,

Zhou³

et al. 2010

Chemotherapy

View full text Add to dashboard Cite

Background: To study the cost-efficacy of docetaxel and pemetrexed as single agents versus platinum-based combination agents in second-line treatment of stage IIIb or IV non-small cell lung cancer (NSCLC) patients by evaluating chemotherapeutic indexes and medical costs. Methods: Treatment responses were evaluated by progression-free survival (PFS), overall survival (OS), hematological and gastrointestinal toxicities. Results: Two hundred and seven stage IIIb or IV NSCLC patients were recruited to this clinical observation retrospective study. Thirty-four subjects were treated with docetaxel (group A), 98 with platinum-based doublet chemotherapy with docetaxel (group B), 42 with pemetrexed (group C), and 33 patients with platinum-based doublet combination therapy with pemetrexed (group D). The average PFS of groups A and B was 3.28 and 4.58 months, respectively (p = 0.042). The mean PFS of groups C and D was 3.1 and 4.98 months, respectively (p = 0.017). The mean OS of these groups was 12.88, 13.17, 12.40 and 13.04 months, respectively, without significant differences. The total medical costs in these four groups amounted to USD 5,533, 7,745, 8,569 and 15,291, respectively. Conclusions: Platinum-based doublet chemotherapy with docetaxel or pemetrexed could significantly increase PFS, however, without significant OS improvement in comparison with using them as single agents. The medical expenses associated with doublet therapy were much higher than those associated with single therapy with a significant portion of the medical expenses spent on treating hematological and gastrointestinal toxicity.

show abstract

Section: Discussionmentioning

confidence: 99%

A Cost-Effectiveness Analysis of Docetaxel versus Pemetrexed in Second-Line Chemotherapy for Stage IIIb or IV Non-Small Cell Lung Cancer in China

Yang

Chen²,

Zhou³

et al. 2010

Chemotherapy

View full text Add to dashboard Cite

show abstract

“…Several clinical trials, using weekly docetaxel monotherapy, have been performed for NSCLC. However, these prior studies had different docetaxel doses (range, 25 to 40 mg/m 2 ) and in addition, the sequence of weeks with and without treatment differed ( 10 - 13 , 16 - 19 , 21 - 24 ). Three randomized phase III trials that compared docetaxel administered weekly with every 3 weeks, in previously treated NSCLC patients, demonstrated that weekly docetaxel regimens had a similar response and survival rates and superior hematological toxicity profiles compared to the 3-weekly schedule ( 10 - 12 ).…”

Section: Discussionmentioning

confidence: 99%

Weekly Low-Dose Docetaxel for Salvage Chemotherapy in Pretreated Elderly or Poor Performance Status Patients with Non-small Cell Lung Cancer

et al. 2008

View full text Add to dashboard Cite

Although docetaxel monotherapy has shown clinical benefits for previously treated patients with advanced non-small cell lung cancer (NSCLC), the efficacy of salvage docetaxel chemotherapy for elderly patients or patients with poor performance status (PS) is controversial. Therefore, we conducted a phase II trial to evaluate the safety and efficacy of weekly low-dose docetaxel monotherapy in these patients. Forty NSCLC patients, who had been previously treated with one or more chemotherapy regimens, received docetaxel at a dose of 25 mg/m2 weekly on days 1, 8, and 15 of a 28-day cycle. All patients were ≥65 yr or had a PS of grade 2 in the cases of <65 yr. Weekly low-dose docetaxel was well-tolerated. Grade 3/4 non-hematologic toxicities were rare; fatigue in 3 patients (8%), anorexia in 3 patients (8%) and stomatitis in 2 patients (5%). Grade 3/4 neutropenia was noted in only one patient (3%). By intent-to-treat analysis, nine patients (23%) had partial responses and eleven patients (28%) demonstrated stable disease. The median progression-free survival and overall survival were 9.9 weeks and 37.7 weeks, respectively. Weekly low-dose docetaxel therapy provides a reasonable alternative for NSCLC salvage treatment in pretreated elderly patients or in patients with a reduced PS.

show abstract

“…For patients with advanced non-small cell lung cancer (NSCLC) and no targetable mutations, cytotoxic chemotherapies, including DNAdamaging or anti-mitotic agents, achieve response rates of 7-21%, as per Response Evaluation Criteria in Solid Tumors (RECIST), when used as single agents in the second-and/or third-line treatment setting [1][2][3][4][5][6][7].…”

Section: Introductionmentioning

confidence: 99%

A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer

et al. 2022

View full text Add to dashboard Cite

Objectives: Berzosertib (formerly M6620, VX-970) is an intravenous, highly potent and selective, first-in-class ataxia telangiectasia and Rad3-related (ATR) protein kinase inhibitor. We assessed the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of berzosertib plus gemcitabine in an expansion cohort of patients with advanced non-small cell lung cancer (NSCLC). The association of efficacy with TP53 status and other tumor markers was also explored. Materials and methods: Adult patients with advanced histologically confirmed NSCLC received berzosertib 210 mg/m 2 (days 2 and 9) and gemcitabine 1000 mg/m 2 (days 1 and 8) at the recommended phase 2 dose established in the dose escalation part of the study. Results: Thirty-eight patients received at least one dose of study treatment. The most common treatmentemergent adverse events were fatigue (55.3%), anemia (52.6%), and nausea (39.5%). Gemcitabine had no apparent effect on the PK of berzosertib. The objective response rate (ORR) was 10.5% (4/38, 90% confidence interval [CI]: 3.7-22.5%). In the exploratory analysis, the ORR was 30.0% (3/10, 90% CI: 9.0-61.0%) in patients with high loss of heterozygosity (LOH) and 11.0% (1/9, 90% CI: 1.0-43.0%) in patients with low LOH. The ORR was 33.0% (2/6, 90% CI: 6.0-73.0%) in patients with high tumor mutational burden (TMB), 12.5% (2/16, 90%

show abstract

Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients

Cited by 7 publications

References 21 publications

A Cost-Effectiveness Analysis of Docetaxel versus Pemetrexed in Second-Line Chemotherapy for Stage IIIb or IV Non-Small Cell Lung Cancer in China

A Cost-Effectiveness Analysis of Docetaxel versus Pemetrexed in Second-Line Chemotherapy for Stage IIIb or IV Non-Small Cell Lung Cancer in China

Weekly Low-Dose Docetaxel for Salvage Chemotherapy in Pretreated Elderly or Poor Performance Status Patients with Non-small Cell Lung Cancer

A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer

Contact Info

Product

Resources

About